Ibrutinib with rituximab in previously untreated CLL: Indication of added benefit over FCR
The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL). […]
Self-reports of smell and taste changes provide earlier markers of the spread of infection of SARS-CoV-2 than current governmental indicators, […]indication
Smell and taste changes provide early indication of COVID-19 community spread